Renal Cell Carcinoma

This is a type of kidney cancer. It's a group of different types of cancer that start in the kidney cells. It's a type of kidney cancer.

Condition

What people with Renal Cell Carcinoma report

Every report comes from a Lived member, sent anonymously.

Have you had Nephrectomy for Renal Cell Carcinoma?

NameHow it went

About Renal Cell Carcinoma

What It Is

Renal cell carcinoma (RCC), also called renal cell cancer, is a cancer that starts in the lining of the tiny tubes inside the kidney that filter blood and make urine. It is by far the most common kidney cancer in adults, accounting for about 9 in 10 cases. It usually grows as a single tumor in one kidney, although some people have more than one tumor or tumors in both kidneys. RCC comes in several subtypes, named for how the cells look under a microscope. Clear cell RCC is the most common, making up about 7 in 10 cases. Papillary and chromophobe RCC are the next most common, and collecting duct carcinoma and other subtypes are rare. The subtype matters because it can change which treatments work best and can point to an inherited cause. Early RCC often causes no symptoms. Many tumors are now found by accident on a CT (computed tomography) scan or ultrasound done for some other reason, often while they are still small and confined to the kidney. Cancers that start in the part of the kidney that collects urine (the renal pelvis), and Wilms tumor in children, are different diseases with different treatment.

Causes & Risk Factors

RCC develops when changes in kidney cells allow them to grow and divide out of control. Most cases have no single identifiable cause, but several factors raise the risk. Smoking is one of the most important, and the extra risk falls slowly after quitting. Excess body weight, high blood pressure and advanced kidney disease, particularly in people on long-term dialysis, also increase risk. RCC is about twice as common in men as in women, and workplace exposure to chemicals such as trichloroethylene or cadmium has been linked to it. A small share of cases come from inherited conditions, such as von Hippel-Lindau disease, which tends to cause clear cell RCC at a younger age and sometimes in both kidneys. A kidney cancer diagnosed young, several tumors, or relatives with kidney cancer can be reasons to consider genetic counseling. Having a risk factor does not mean someone will get RCC, and many people who develop it have none of these factors.

How It's Diagnosed

Diagnosis usually starts with imaging. A CT scan of the abdomen, typically with contrast dye injected into a vein, shows the size and location of a kidney mass and whether it looks solid, which is more suspicious than a fluid-filled cyst. MRI (magnetic resonance imaging) or ultrasound may be used instead, for example when kidney function makes contrast dye a concern. Blood and urine tests do not diagnose RCC, but they check kidney function, blood counts and general fitness for treatment. Unlike most cancers, RCC can often be diagnosed with reasonable confidence from imaging alone, and the diagnosis is then confirmed when the tumor is removed and examined. A needle biopsy, guided by CT or ultrasound, is used when imaging is unclear, or when the plan is to watch a small tumor or treat it without surgery. Staging describes how far the cancer has spread. Stage I and II tumors are still confined to the kidney (stage I is 7 centimeters or smaller; stage II is larger). Stage III means spread into nearby lymph nodes, the large veins draining the kidney or the fat around it. Stage IV means spread beyond that, often to the lungs, bones, liver or brain. A chest CT and sometimes a bone scan help with staging. The pathology report also gives the subtype and grade, which describes how abnormal the cells look and helps estimate the risk of the cancer returning.

Treatment Options

Treatment depends mainly on the stage, the subtype, kidney function and overall health. For cancer confined to the kidney, surgery is the main treatment and is often curative. A partial nephrectomy removes only the tumor and a margin of healthy tissue, preserving kidney function, and is often preferred for smaller tumors. A radical nephrectomy removes the whole kidney and is often used for larger or centrally placed tumors. Most people live well with one healthy kidney, but protecting kidney function matters more for people who already have kidney disease. Not every small tumor needs immediate treatment. Some grow slowly and may never cause harm, so active surveillance, with regular imaging and treatment only if the tumor grows or changes, can be reasonable, especially for older people or those with other serious health problems. Ablation, which destroys the tumor by freezing (cryoablation) or heat (radiofrequency ablation), and focused radiation called stereotactic body radiation therapy are options for people who cannot have or prefer to avoid surgery; they control the cancer about as well in terms of spread, but the tumor may be somewhat more likely to come back in the same spot. After surgery for clear cell RCC with a high risk of returning, a year of the immunotherapy drug pembrolizumab (Keytruda) may be offered to lower that risk. For advanced or metastatic RCC, medicines are the main treatment and usually aim for long-term control rather than cure. Immune checkpoint inhibitors, such as pembrolizumab or nivolumab (Opdivo), release a brake on the immune system so it can attack the cancer. Targeted drugs, such as axitinib (Inlyta) or cabozantinib (Cabometyx), are pills that block signals tumors use to grow and form new blood vessels. First treatment often combines two of these, either two immunotherapy drugs or one immunotherapy drug with a targeted pill. If one treatment stops working, others can often be tried. These medicines have trade-offs that shape the choice. Targeted pills commonly cause high blood pressure, diarrhea, fatigue and sore hands and feet, which often improve with dose adjustments. Checkpoint inhibitors are usually easier day to day, but they can trigger the immune system to inflame organs such as the bowel, lungs, liver or thyroid, sometimes seriously. Some rare subtypes, such as collecting duct carcinoma, are often treated with chemotherapy instead. Surgery, ablation or radiation may still be used in advanced disease to remove limited spots of spread or relieve pain or bleeding, and clinical trials are an option at many stages.

What to Expect

The outlook depends heavily on stage. When RCC is found while still confined to the kidney, about 93 in 100 people are alive five years later compared with people without the cancer. That figure is about 76 in 100 when it has spread to nearby tissue or lymph nodes and about 19 in 100 when it has spread to distant organs. These numbers come from people diagnosed several years ago, before some current treatments were widely used, and cannot predict any one person's course. A person can live a normal life with one working kidney, or even part of one. After surgery, kidney function and blood pressure are worth checking over time, and some medicines may need dose adjustment. RCC can come back many years after treatment, so follow-up continues long after surgery, usually with periodic scans and blood tests that become less frequent over time. For people with advanced disease, treatment is often ongoing for months or years, with regular visits to check blood pressure, blood tests and side effects, and scans every few months to see whether the cancer is responding. Living with cancer that is controlled rather than gone can be stressful, and support from the care team, counseling or support groups can help.

When to Seek Help

See a doctor if you notice blood in the urine, a lump in your side or lower back, pain in one side that does not go away, or unexplained weight loss, loss of appetite, fever or tiredness. These are more often caused by infections, kidney stones or other benign problems, but they deserve a check. If a kidney mass has been found on a scan, ask for a clear plan for further testing or follow-up rather than leaving it unaddressed. During treatment, contact your care team promptly about new or worsening symptoms. On immunotherapy, report any new symptom right away, during treatment or after it ends, especially diarrhea, a new cough or shortness of breath, yellowing skin or eyes, severe tiredness or a rash, because early treatment of immune-related side effects can prevent serious harm. On targeted pills, call if home blood pressure readings run well above the goal your team set or if side effects make it hard to eat, drink or keep up daily activities. After treatment, mention new bone pain, a persistent cough or other new symptoms at follow-up, or sooner if they are troubling.

Questions to Ask Your Doctor

  1. 1.What subtype, stage and grade is my cancer, and what do they mean for my risk of it coming back?
  2. 2.Is active surveillance, partial nephrectomy, removal of the whole kidney or ablation the best fit for my tumor and my kidney function?
  3. 3.Would treatment after surgery to lower the risk of recurrence make sense for me, and what are its realistic benefits and side effects?
  4. 4.If the cancer has spread, what is the goal of treatment, and how will we decide between immunotherapy combinations?
  5. 5.What will my follow-up schedule look like, and should I or my family consider genetic counseling?

Last reviewed • Oct 2026

Educational content, not medical advice.